{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:56:39Z","timestamp":1794534999673,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT22-17"],"award-info":[{"award-number":["SU2C-AACR-DT22-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA217848"],"award-info":[{"award-number":["U01CA217848"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine\/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival. This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with\u00a0indoleamine 2,3-dioxygenase\/tryptophan 2,3-dioxygenase \u00a0 (IDO\/TDO) inhibitors.<\/jats:p>","DOI":"10.1038\/s41467-019-12361-9","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T10:03:27Z","timestamp":1569405807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Metabolomic adaptations and correlates of survival to immune checkpoint blockade"],"prefix":"10.1038","volume":"10","author":[{"given":"Haoxin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carino","family":"Gurjao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-5632","authenticated-orcid":false,"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuba","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wind-Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-5616","authenticated-orcid":false,"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Stephen Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-9803","authenticated-orcid":false,"given":"William R.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi A.","family":"Garraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9245","authenticated-orcid":false,"given":"Clary B.","family":"Clish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"12361_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. New Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"New Engl. J. Med."},{"key":"12361_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. New Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"New Engl. J. Med."},{"key":"12361_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. New Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"New Engl. J. Med."},{"key":"12361_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"12361_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"12361_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"12361_CR7","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).","journal-title":"Sci. Transl. Med."},{"key":"12361_CR8","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. cancer Res. 22, 5461\u20135471 (2016).","journal-title":"Clin. cancer Res."},{"key":"12361_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"P Chen","year":"2016","unstructured":"Chen, P. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"12361_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ni.3415","volume":"17","author":"C Chang","year":"2016","unstructured":"Chang, C. & Pearce, E. L. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17, 364\u2013368 (2016).","journal-title":"Nat. Immunol."},{"key":"12361_CR11","doi-asserted-by":"crossref","first-page":"2855 LP","DOI":"10.1158\/1538-7445.AM2015-2855","volume":"75","author":"WJ Urba","year":"2015","unstructured":"Urba, W. J. et al. Abstract 2855: immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma. Cancer Res. 75, 2855 LP\u20132855 (2015).","journal-title":"Cancer Res."},{"key":"12361_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u20131274 (2003).","journal-title":"Nat. Med."},{"key":"12361_CR13","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1073\/pnas.1113873109","volume":"109","author":"L Pilotte","year":"2012","unstructured":"Pilotte, L. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109, 2497\u20132502 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"12361_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 (2017).","journal-title":"Cell"},{"key":"12361_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454\u2013463 (2004).","journal-title":"J. Clin. Oncol."},{"key":"12361_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","volume":"25","author":"H Li","year":"2019","unstructured":"Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. 25, 850\u2013860 (2019).","journal-title":"Nat. Med."},{"key":"12361_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","volume":"189","author":"DH Munn","year":"1999","unstructured":"Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363\u20131372 (1999).","journal-title":"J. Exp. Med."},{"key":"12361_CR18","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","volume":"164","author":"P Hwu","year":"2000","unstructured":"Hwu, P. et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596\u20133599 (2000).","journal-title":"J. Immunol."},{"key":"12361_CR19","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1126\/science.1073514","volume":"297","author":"DH Munn","year":"2002","unstructured":"Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867\u20131870 (2002).","journal-title":"Science"},{"key":"12361_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389\u20131402 (2013).","journal-title":"J. Exp. Med."},{"key":"12361_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study.\u00a0\u00a0Lancet Oncol.\u00a020, 1083\u20131097 (2019).","journal-title":"Lancet Oncol"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12361-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:25:35Z","timestamp":1671240335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["12361"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-12361-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.J., C.H. and M.W. are employees of Bristol-Myers Squibb. G.J.F. has patents\/pending royalties on the PD-1 pathway from Roche, Merck, Bristol Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Dako, and Novartis and has served on advisory boards for CoStim, Novartis, Roche, Eli Lilly, Bristol-Myers-Squibb, Seattle Genetics, Bethyl Laboratories, Xios, and Quiet. F.S.H. receives consulting fees from Bristol Myers-Squibb, Merck, EMD-Serono, Novartis, Celldex, Amgen, Genentech\/Roche, Incyte, Bayer, Partners Therapeutics, Sanofi, Pfizer and is on the advisory board for Apricity, Aduro, Pionyr, 7 Hills Pharma, Verastem, Compass Therapeutics, Takeda and holds equity and is on the advisory board for Torque. L.A.G. was a paid consultant for Novartis, Foundation Medicine, and Boehringer-Ingelheim; he held equity in Foundation Medicine and was a recipient of a grant from Novartis. L.A.G. is an employee of Roche. M.G. receives research funding from Bristol Myers-Squibb\u00a0and Merck. T.K.C. receives research funds from AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Takeda. T.K.C. receives honoraria from AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics. T.K.C has consulting or advisory role for AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group. T.K.C. does not serve within a speaker\u2019s bureau. T.K.C. does not have leadership or employment in for-profit companies. Other present or past leadership roles of T.K.C. include Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber), member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney cancer Association Medical and Scientific Steering Committee). H.L.,\u00a0T.K.C.\u00a0and M.G. have\u00a0pending patents for biomarkers of immune checkpoint blockers. T.K.C.\u00a0has stock ownership in Pionyr and Tempest.\u00a0For T.K.C., travel, accommodations, and expenses, in relation to consulting, advisory roles, honoraria, medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4346"}}